<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03383523</url>
  </required_header>
  <id_info>
    <org_study_id>DNDI-EMO-03</org_study_id>
    <secondary_id>2017-003091-31</secondary_id>
    <nct_id>NCT03383523</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study of Emodepside IR-tablets and Solution</brief_title>
  <official_title>Phase1,Randomized,Open-Label,Parallel-Group,Relative Bioavailability Study to Investigate PK,Including Food Effect,Safety and Tolerability of Single Doses of New Immediate Release Tablet Formulations of Emodepside (BAY 44-4400),Compared to Oral Solution,in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Drugs for Neglected Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bill and Melinda Gates Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Drugs for Neglected Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they
      will be compared to the oral liquid service formulation (LSF) used in the FIH Single
      Ascending Dose study (DNDi-EMO-001 study) (CT.gov identifier: NCT02661178)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is an urgent need for a macrofilaricidal drug, killing or sterilizing permanently O.
      volvulus adult worms, which could be used in individual case management and, after
      appropriate testing, as an alternative drug to ivermectin in MDA programs. Emodepside is a
      promising candidate to kill the adult and sexually mature O. volvulus. Emodepside was shown
      to be macrofilaricidal against a variety of filarial nematodes and is a registered drug for
      animal health, commercialized by Bayer AG under the name of Profender速 (in combination with
      praziquantel) or Procox速 (in combination with toltrazuril).

      A first-in-human (FIH) double-blind, placebo-controlled study of single ascending doses of
      emodepside in healthy Caucasian men has been conducted and the preliminary results are
      favourable, and support continuing the Phase I development program. For this reason, new
      tablet formulations have been developped and the present study will evaluate bioavailability,
      PK safety and tolerability, and as well food effect of single doses of 2 new immediate
      release (IR)-tablet formulations of emodepside compared to the oral liquid service
      formulation (LSF) used in the FIH study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 26, 2017</start_date>
  <completion_date type="Actual">March 26, 2018</completion_date>
  <primary_completion_date type="Actual">March 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a single-centre, open-label, randomized, parallel-group relative bioavailability study in healthy men. The study will be done in 2 parts, as follows:
Part 1 - single oral doses of 5 mg emodepside will be tested:
Part 1a - the LSF (reference formulation) and 2 new IR-tablet formulations (test formulations) will be administered in the fasted state.
Part 1b - the 2 new IR-tablet formulations will be administered in the fed state (high-fat, high-calorie meal).
Part 2 - single oral doses of 10 mg emodepside will be tested: depending on the results from Part 1, one or both IR-tablet formulations will be administered in the fasted state.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PK (AUC0-7d) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution.</measure>
    <time_frame>means from zero to 7 days</time_frame>
    <description>Means AUC from zero to 7 days (AUC0-7d) = means area under the plasma concentration-time curve from time zero (pre-dose) to 7 days. To create the curve, the following PK Timepoints have been collected: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3,4,6,8,12,36,48,72,120 and 168h post dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK (Cmax) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution.</measure>
    <time_frame>7 days</time_frame>
    <description>Cmax means maximum observed plasma concentration. To create the PK curve, the following PK timepoints have been collected: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3,4,6,8,12,36,48,72,120 and 168h post dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With Treatment-related Adverse Events</measure>
    <time_frame>7 days</time_frame>
    <description>number of participants with treatment-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With Physical Examination Findings</measure>
    <time_frame>7 days</time_frame>
    <description>number of participants with abnormal physical examination (PE) findings. Standard examination done on head, ears, eyes, nose, thyroid, lymph node, back, neck, lungs, skin, abdomen, chest. The details are listed in protocol section 8.11.3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With Neurological Examination Findings</measure>
    <time_frame>7 days</time_frame>
    <description>Number of participants with abnormal neurological examination (NE) findings</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With Vital Signs Findings</measure>
    <time_frame>7 days</time_frame>
    <description>number of participants with vital signs (VS) findings. The vital signs ranges are the following Supine Systolic BP : 85-160mm HG, Supine Diastolic BP: 40-90mm HG, Supine HR: 35-100 beats/min. Details are described in the protocol section 8.11.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With 12-lead ECG Findings</measure>
    <time_frame>7 days</time_frame>
    <description>number of participants with 12-lead ECG findings. The ECG reference ranges used are the following: ventricular rate: 45-100beats/min, PR interval:120-220msec, QRS:&lt;120msec, QTc:&lt;430msec</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability as Measured by Number of Participants With Clinical Laboratory Tests Findings</measure>
    <time_frame>7 days</time_frame>
    <description>number of participants with relevant abnormal laboratory tests results</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Filariasis</condition>
  <arm_group>
    <arm_group_label>Part 1a - treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg emodepside LSF, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1a - treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg emodepside IR-tablet #406, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1a - treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg emodepside IR-tablet #416, fasted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1b - treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg emodepside IR-tablet #406, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1b - treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg emodepside IR-tablet #416, fed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - treatment F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - treatment G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emodepside (BAY 44-4400)</intervention_name>
    <description>2 tablets compared to the liquid formulation</description>
    <arm_group_label>Part 1a - treatment A</arm_group_label>
    <arm_group_label>Part 1a - treatment B</arm_group_label>
    <arm_group_label>Part 1a - treatment C</arm_group_label>
    <arm_group_label>Part 1b - treatment D</arm_group_label>
    <arm_group_label>Part 1b - treatment E</arm_group_label>
    <arm_group_label>Part 2 - treatment F</arm_group_label>
    <arm_group_label>Part 2 - treatment G</arm_group_label>
    <other_name>Profender速 (in combination with praziquantel) FOR VETERINARY USE</other_name>
    <other_name>Procox速 (in combination with toltrazuril) FOR VETERINARY USE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male, Caucasian volunteers, deemed healthy based on a clinical history, physical
             examination, ECG, vital signs, and laboratory tests of blood and urine.

          2. 18 to 45 years of age

          3. Normal body weight (Body Mass Index (BMI); Quetelet index) in the range 18.0 to 30.1
             kg/m2 at screening

          4. Mean blood pressure and heart rate (from the triplicate readings) in the supine
             position at the screening assessment outside one (or more) of the ranges: 90-140 mm Hg
             systolic BP 60-90 mm Hg diastolic BP 45-100 beats/min HR

          5. Sufficient intelligence to understand the nature of the trial and any hazards of
             participating in it. Ability to communicate satisfactorily with the Investigator and
             to participate in, and comply with the requirements of, the entire trial

          6. Willingness to give written consent to participate, after reading the information and
             consent form, and after having the opportunity to discuss the trial with the
             Investigator or his delegate

          7. Willingness to give written consent to have data entered into The Overvolunteering
             Prevention System (TOPS)

          8. Willingness to follow contraception requirements of the study, from the first dose of
             the IMP until 90 days after dosing and inform HMR as soon as possible if their partner
             becomes pregnant in the 90 days after dosing

             Exclusion Criteria:

          9. Administration of a licensed or unlicensed medicinal product as part of another
             clinical trial in the 3 months before the first dose of study medication, or within 5
             half-lives of administration of a medicinal product given in the previous study
             (whichever is longer), or otherwise in the follow-up period for any clinical trial

         10. Clinically relevant abnormal medical history, concurrent medical condition, acute or
             chronic illness, or history of chronic illness (such as diabetes mellitus or other
             abnormalities of glucose homeostasis) sufficient to invalidate the subject's
             participation in the trial or make it unnecessarily hazardous

         11. Past surgery (e.g. stomach bypass) or medical condition that might affect absorption
             of the study drug when taken orally

         12. Presence of abnormal physical findings, ECG, or laboratory values at the screening
             assessment that could interfere with the objectives of the trial or the safety of the
             subject

         13. Loss of more than 400 mL of blood within the 3 months before admission

         14. Clinically relevant history of vital organ disease, or other organ or central nervous
             system disease (e.g. diabetes mellitus, liver disease, seizures, etc.)

         15. Current or previous medical or psychiatric disorder that, in the opinion of the
             Investigator or the Sponsor, would increase the risk and ability to participate in
             and/or complete the study

         16. Positive test for hepatitis B, hepatitis C or HIV

         17. Febrile illness (e.g. fever) within 1 week before the first dose of study medication

         18. History of a severe allergy, non-allergic drug reaction, severe adverse reaction to
             any drug, or multiple drug allergies

         19. Hypersensitivity to any ingredient of the study medication, including the active
             ingredient (emodepside)

         20. Presence or history of drug or alcohol abuse in the last year, or intake of more than
             21 units (1 unit = 1/2 pint of beer, 1 small glass of wine or 1 measure of spirits) of
             alcohol weekly

         21. Regular daily consumption of more than one litre of beverages containing xanthine

         22. Daily consumption of more than 10 cigarettes or more than 6 grams (1/4 ounce) of
             tobacco

         23. Use of a prescription medicine during the 28 days before the dose of study medication,
             or use of an over-the-counter medicine (with exception of acetaminophen
             (paracetamol)), during the 7 days before the dose of study medication

         24. Use, within 14 days before the dose of study medication, of dietary supplements or
             herbal remedies (such as St John's Wort) that are known to be inducers or inhibitors
             of CYP3A4, or other co-medications known to be relevant substrates of CYP3A4 (see list
             in the Study Procedures Manual)

         25. Use, within 14 days before the dose of study medication, of dietary supplements or
             herbal remedies that are known to be strong inhibitors of P-gp, or other
             co-medications known to be relevant substrates of P-gp (see list in the Study
             Procedures Manual)

         26. Relevant pathological abnormalities in the ECG at screening, such as:

             second or third-degree atrioventricular (AV) block prolongation of the QRS complex &gt;
             120 msec, QTc-interval (QTcB or QTcF) &gt; 450 msec. The mean of the triplicate ECG
             readings will be used to assess eligibility.

         27. Evidence of drug abuse (via urine testing) at the screening assessment or admission to
             the ward

         28. Use of excluded therapies that may impact on the interpretation of study results in
             the opinion of the Investigator or Sponsor

         29. Objection by General Practitioner (GP) to subject entering trial

         30. History of residing for 6 or more continuous months during the last 3 years in regions
             with endemic parasitic infections, as determined by the Investigator

         31. Possibility that subject will not cooperate with the requirements of the protocol
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>male only</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy Dennison</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hammersmith Medicines Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR) Limited</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 27, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2017</study_first_posted>
  <results_first_submitted>May 22, 2019</results_first_submitted>
  <results_first_submitted_qc>February 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2020</results_first_posted>
  <last_update_submitted>February 20, 2020</last_update_submitted>
  <last_update_submitted_qc>February 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filariasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Praziquantel</mesh_term>
    <mesh_term>Emodepside</mesh_term>
    <mesh_term>Toltrazuril</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03383523/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT03383523/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential volunteers contacted HMR by telephone or email if they were interested in the study. HMR contacted eligible volunteers who had registered an interest in doing this study to invite them to take part. Recruitment of participants started on 26 October 2017 (FSFV) and finished on 26 March 2018 (LSLV).</recruitment_details>
      <pre_assignment_details>screening details: to check they were healthy and eligible for the study, volunteers had a full examination at screening including physical and neurological examination, vital signs, 12-lead ECG monitoring, safety blood tests (hematology, biochemistry, coagulation and urinalysis), drug screen, alcohol breath test and serology</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1a - Treatment A</title>
          <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="P2">
          <title>Part 1a - Treatment B</title>
          <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="P3">
          <title>Part 1a - Treatment C</title>
          <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="P4">
          <title>Part 1b - Treatment D</title>
          <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="P5">
          <title>Part 1b - Treatment E</title>
          <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="P6">
          <title>Part 2 - Treatment F</title>
          <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="P7">
          <title>Part 2 - Treatment G</title>
          <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="11"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Healthy Caucasian males subjects</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1a - Treatment A</title>
          <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="B2">
          <title>Part 1a - Treatment B</title>
          <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="B3">
          <title>Part 1a - Treatment C</title>
          <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="B4">
          <title>Part 1b - Treatment D</title>
          <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="B5">
          <title>Part 1b - Treatment E</title>
          <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="B6">
          <title>Part 2 - Treatment F</title>
          <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="B7">
          <title>Part 2 - Treatment G</title>
          <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="11"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="10"/>
            <count group_id="B8" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="21" upper_limit="38"/>
                    <measurement group_id="B2" value="32.4" lower_limit="18" upper_limit="44"/>
                    <measurement group_id="B3" value="32.2" lower_limit="23" upper_limit="43"/>
                    <measurement group_id="B4" value="32.6" lower_limit="23" upper_limit="44"/>
                    <measurement group_id="B5" value="30.5" lower_limit="18" upper_limit="42"/>
                    <measurement group_id="B6" value="30.5" lower_limit="20" upper_limit="44"/>
                    <measurement group_id="B7" value="29.8" lower_limit="18" upper_limit="38"/>
                    <measurement group_id="B8" value="31.1" lower_limit="18" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="10"/>
                    <measurement group_id="B8" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PK (AUC0-7d) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution.</title>
        <description>Means AUC from zero to 7 days (AUC0-7d) = means area under the plasma concentration-time curve from time zero (pre-dose) to 7 days. To create the curve, the following PK Timepoints have been collected: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3,4,6,8,12,36,48,72,120 and 168h post dose</description>
        <time_frame>means from zero to 7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1a - Treatment A</title>
            <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O2">
            <title>Part 1a - Treatment B</title>
            <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O3">
            <title>Part 1a - Treatment C</title>
            <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O4">
            <title>Part 1b - Treatment D</title>
            <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O5">
            <title>Part 1b - Treatment E</title>
            <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O6">
            <title>Part 2 - Treatment F</title>
            <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Treatment G</title>
            <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
        </group_list>
        <measure>
          <title>PK (AUC0-7d) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution.</title>
          <description>Means AUC from zero to 7 days (AUC0-7d) = means area under the plasma concentration-time curve from time zero (pre-dose) to 7 days. To create the curve, the following PK Timepoints have been collected: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3,4,6,8,12,36,48,72,120 and 168h post dose</description>
          <units>h.ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1215" spread="37.2"/>
                    <measurement group_id="O2" value="852" spread="19.1"/>
                    <measurement group_id="O3" value="931" spread="23.3"/>
                    <measurement group_id="O4" value="674" spread="32.1"/>
                    <measurement group_id="O5" value="733" spread="34.9"/>
                    <measurement group_id="O6" value="1609" spread="35.9"/>
                    <measurement group_id="O7" value="1943" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK (Cmax) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution.</title>
        <description>Cmax means maximum observed plasma concentration. To create the PK curve, the following PK timepoints have been collected: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3,4,6,8,12,36,48,72,120 and 168h post dose</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1a - Treatment A</title>
            <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O2">
            <title>Part 1a - Treatment B</title>
            <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O3">
            <title>Part 1a - Treatment C</title>
            <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O4">
            <title>Part 1b - Treatment D</title>
            <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O5">
            <title>Part 1b - Treatment E</title>
            <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O6">
            <title>Part 2 - Treatment F</title>
            <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Treatment G</title>
            <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
        </group_list>
        <measure>
          <title>PK (Cmax) of Two New Tablet Formulations of Emodepside in Comparison to the Liquid Formulation (LSF) Oral Solution.</title>
          <description>Cmax means maximum observed plasma concentration. To create the PK curve, the following PK timepoints have been collected: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3,4,6,8,12,36,48,72,120 and 168h post dose</description>
          <units>ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5" spread="20.1"/>
                    <measurement group_id="O2" value="41.9" spread="20.0"/>
                    <measurement group_id="O3" value="54.2" spread="35.3"/>
                    <measurement group_id="O4" value="27.1" spread="26.8"/>
                    <measurement group_id="O5" value="36.2" spread="39.8"/>
                    <measurement group_id="O6" value="71.7" spread="28.5"/>
                    <measurement group_id="O7" value="135" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability as Measured by Number of Participants With Treatment-related Adverse Events</title>
        <description>number of participants with treatment-related adverse events</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1a - Treatment A</title>
            <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O2">
            <title>Part 1a - Treatment B</title>
            <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O3">
            <title>Part 1a - Treatment C</title>
            <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O4">
            <title>Part 1b - Treatment D</title>
            <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O5">
            <title>Part 1b - Treatment E</title>
            <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O6">
            <title>Part 2 - Treatment F</title>
            <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Treatment G</title>
            <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Number of Participants With Treatment-related Adverse Events</title>
          <description>number of participants with treatment-related adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability as Measured by Number of Participants With Physical Examination Findings</title>
        <description>number of participants with abnormal physical examination (PE) findings. Standard examination done on head, ears, eyes, nose, thyroid, lymph node, back, neck, lungs, skin, abdomen, chest. The details are listed in protocol section 8.11.3</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1a - Treatment A</title>
            <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O2">
            <title>Part 1a - Treatment B</title>
            <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O3">
            <title>Part 1a - Treatment C</title>
            <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O4">
            <title>Part 1b - Treatment D</title>
            <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O5">
            <title>Part 1b - Treatment E</title>
            <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O6">
            <title>Part 2 - Treatment F</title>
            <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Treatment G</title>
            <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Number of Participants With Physical Examination Findings</title>
          <description>number of participants with abnormal physical examination (PE) findings. Standard examination done on head, ears, eyes, nose, thyroid, lymph node, back, neck, lungs, skin, abdomen, chest. The details are listed in protocol section 8.11.3</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of subject with abnormal PE findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number subject with clinically significant finding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability as Measured by Number of Participants With Neurological Examination Findings</title>
        <description>Number of participants with abnormal neurological examination (NE) findings</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1a - Treatment A</title>
            <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O2">
            <title>Part 1a - Treatment B</title>
            <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O3">
            <title>Part 1a - Treatment C</title>
            <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O4">
            <title>Part 1b - Treatment D</title>
            <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O5">
            <title>Part 1b - Treatment E</title>
            <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O6">
            <title>Part 2 - Treatment F</title>
            <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Treatment G</title>
            <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Number of Participants With Neurological Examination Findings</title>
          <description>Number of participants with abnormal neurological examination (NE) findings</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of subject with abnormal NE findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number subject with clinically significant finding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability as Measured by Number of Participants With Vital Signs Findings</title>
        <description>number of participants with vital signs (VS) findings. The vital signs ranges are the following Supine Systolic BP : 85-160mm HG, Supine Diastolic BP: 40-90mm HG, Supine HR: 35-100 beats/min. Details are described in the protocol section 8.11.2</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1a - Treatment A</title>
            <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O2">
            <title>Part 1a - Treatment B</title>
            <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O3">
            <title>Part 1a - Treatment C</title>
            <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O4">
            <title>Part 1b - Treatment D</title>
            <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O5">
            <title>Part 1b - Treatment E</title>
            <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O6">
            <title>Part 2 - Treatment F</title>
            <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Treatment G</title>
            <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Number of Participants With Vital Signs Findings</title>
          <description>number of participants with vital signs (VS) findings. The vital signs ranges are the following Supine Systolic BP : 85-160mm HG, Supine Diastolic BP: 40-90mm HG, Supine HR: 35-100 beats/min. Details are described in the protocol section 8.11.2</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of subject with VS findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number subject with clinically significant finding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability as Measured by Number of Participants With 12-lead ECG Findings</title>
        <description>number of participants with 12-lead ECG findings. The ECG reference ranges used are the following: ventricular rate: 45-100beats/min, PR interval:120-220msec, QRS:&lt;120msec, QTc:&lt;430msec</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1a - Treatment A</title>
            <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O2">
            <title>Part 1a - Treatment B</title>
            <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O3">
            <title>Part 1a - Treatment C</title>
            <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O4">
            <title>Part 1b - Treatment D</title>
            <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O5">
            <title>Part 1b - Treatment E</title>
            <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O6">
            <title>Part 2 - Treatment F</title>
            <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Treatment G</title>
            <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Number of Participants With 12-lead ECG Findings</title>
          <description>number of participants with 12-lead ECG findings. The ECG reference ranges used are the following: ventricular rate: 45-100beats/min, PR interval:120-220msec, QRS:&lt;120msec, QTc:&lt;430msec</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of subject with abnormal ECG findings</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number subject with clinically significant finding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability as Measured by Number of Participants With Clinical Laboratory Tests Findings</title>
        <description>number of participants with relevant abnormal laboratory tests results</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1a - Treatment A</title>
            <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O2">
            <title>Part 1a - Treatment B</title>
            <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O3">
            <title>Part 1a - Treatment C</title>
            <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O4">
            <title>Part 1b - Treatment D</title>
            <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O5">
            <title>Part 1b - Treatment E</title>
            <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O6">
            <title>Part 2 - Treatment F</title>
            <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
          <group group_id="O7">
            <title>Part 2 - Treatment G</title>
            <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability as Measured by Number of Participants With Clinical Laboratory Tests Findings</title>
          <description>number of participants with relevant abnormal laboratory tests results</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of subject with abnormal lab values</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number subject with clinically significant finding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were reported from screening (up to 28 days before dosing) up to Follow up visit (7 days after dosing)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part 1a - Treatment A</title>
          <description>5 mg emodepside LSF, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="E2">
          <title>Part 1a - Treatment B</title>
          <description>5 mg emodepside IR-tablet #406, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="E3">
          <title>Part 1a - Treatment C</title>
          <description>5 mg emodepside IR-tablet #416, fasted
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="E4">
          <title>Part 1b - Treatment D</title>
          <description>5 mg emodepside IR-tablet #406, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="E5">
          <title>Part 1b - Treatment E</title>
          <description>5 mg emodepside IR-tablet #416, fed
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="E6">
          <title>Part 2 - Treatment F</title>
          <description>2 x 5 mg emodepside IR-tablet #406, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
        <group group_id="E7">
          <title>Part 2 - Treatment G</title>
          <description>2 x 5 mg emodepside IR-tablet #416, fasted (may be tested or not, depending on the results of the part 1)
Emodepside (BAY 44-4400): 2 tablets compared to the liquid formulation</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>abdominal disconfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>catheter site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>feeling of relaxation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is an agreement between the PI and the sponsor that restricts the PI's rights to discuss or publish trial results after the trial is completed.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jean Yves Gillon</name_or_title>
      <organization>Drugs for Neglected Diseases Initiative</organization>
      <phone>+41229069232</phone>
      <email>jygillon@dndi.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

